New Chemotherapy for Childhood Acute Lymphoblastic Leukemia Patients
The FDA recently approved a new anticancer therapeutic for treating patients with childhood acute lymphoblastic leukemia (ALL).
Progress Against Cancer
The FDA recently approved a new anticancer therapeutic for treating patients with childhood acute lymphoblastic leukemia (ALL).
The FDA expanded the use of pembrolizumab to treat certain patients with a rare, aggressive type of skin cancer called Merkel cell carcinoma.
The FDA approved a new molecularly targeted therapeutic called gilteritinib for treating certain patients with acute myeloid leukemia (AML).
The FDA approved the first molecularly targeted therapeutic for use based on a tumor biomarker rather than where the cancer originates.
The FDA approved two separate molecularly targeted therapeutics for treating patients aged 75 or older with acute myeloid leukemia (AML).
The FDA expanded the use of the immunotherapy pembrolizumab to include the treatment of certain patients with liver cancer.
The FDA approved a molecularly targeted therapeutic for treating certain patients with metastatic non-small cell lung cancer.
The FDA approved a targeted therapeutic for treating patients with breast cancer that tests positive for a cancer-associated BRCA1 or BRCA2 mutations.
The FDA approved a molecularly targeted therapeutic for treating certain patients with non-small cell lung cancer.
The FDA approved a new molecularly targeted therapeutic called for treating certain patients with blood cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now